Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Asalyxa Bio, a US-based developer of immune cell-targeted therapeutics spun out of University of Michigan, has completed a $2m seed round co-led by Research Bridge Partners and ID Ventures, with participation from the Biosciences Research and Commercialization Center at Western Michigan University, Michigan Rise Pre-Seed Fund III, Ann Arbor Spark, Woodward Angels and undisclosed investors. The round will allow Asalyxa to move its lead asset into the clinic.
…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
